CL2023001325A1 - Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina - Google Patents
Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicininaInfo
- Publication number
- CL2023001325A1 CL2023001325A1 CL2023001325A CL2023001325A CL2023001325A1 CL 2023001325 A1 CL2023001325 A1 CL 2023001325A1 CL 2023001325 A CL2023001325 A CL 2023001325A CL 2023001325 A CL2023001325 A CL 2023001325A CL 2023001325 A1 CL2023001325 A1 CL 2023001325A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- treatment
- disorders mediated
- tachykinin receptors
- tachykinin
- Prior art date
Links
- 102000007124 Tachykinin Receptors Human genes 0.000 title abstract 2
- 108010072901 Tachykinin Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000035475 disorder Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102100037342 Substance-K receptor Human genes 0.000 abstract 1
- 101710116609 Substance-K receptor Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206509 | 2020-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001325A1 true CL2023001325A1 (es) | 2023-12-15 |
Family
ID=73198203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001325A CL2023001325A1 (es) | 2020-11-09 | 2023-05-08 | Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230406883A1 (enExample) |
| EP (1) | EP4240749A1 (enExample) |
| JP (1) | JP2023551122A (enExample) |
| KR (1) | KR20230106616A (enExample) |
| CN (1) | CN116745310A (enExample) |
| AU (1) | AU2021374843A1 (enExample) |
| CA (1) | CA3197916A1 (enExample) |
| CL (1) | CL2023001325A1 (enExample) |
| CO (1) | CO2023007404A2 (enExample) |
| IL (1) | IL302745A (enExample) |
| MX (1) | MX2023005408A (enExample) |
| PE (1) | PE20231952A1 (enExample) |
| WO (1) | WO2022096736A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023118263A1 (en) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonists for treatment of eating disorder |
| CN117384258B (zh) * | 2023-10-12 | 2024-07-26 | 湖南中晟全肽生物科技股份有限公司 | 一种神经激肽受体2（nk2r）激动剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660247A3 (en) * | 2009-05-08 | 2014-09-03 | Chongxi Yu | High penetration prodrug compositions of peptides and peptide-related compounds |
| CA2918245C (en) * | 2013-08-01 | 2022-08-30 | Dignify Therapeutics, Inc. | Compositions and methods for inducing urinary voiding and defecation |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| US11352391B2 (en) * | 2017-09-21 | 2022-06-07 | Dignify Therapeutics, Llc | Compositions for inducing urinary voiding and defecation |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| KR20220084035A (ko) * | 2019-10-17 | 2022-06-21 | 유니버시티 오브 코펜하겐 | Tacr2의 효능제 |
-
2021
- 2021-11-09 IL IL302745A patent/IL302745A/en unknown
- 2021-11-09 CN CN202180089751.3A patent/CN116745310A/zh active Pending
- 2021-11-09 WO PCT/EP2021/081057 patent/WO2022096736A1/en not_active Ceased
- 2021-11-09 PE PE2023001563A patent/PE20231952A1/es unknown
- 2021-11-09 CA CA3197916A patent/CA3197916A1/en active Pending
- 2021-11-09 JP JP2023528102A patent/JP2023551122A/ja not_active Ceased
- 2021-11-09 AU AU2021374843A patent/AU2021374843A1/en active Pending
- 2021-11-09 MX MX2023005408A patent/MX2023005408A/es unknown
- 2021-11-09 EP EP21802379.4A patent/EP4240749A1/en active Pending
- 2021-11-09 KR KR1020237016448A patent/KR20230106616A/ko active Pending
- 2021-11-09 US US18/252,056 patent/US20230406883A1/en active Pending
-
2023
- 2023-05-08 CL CL2023001325A patent/CL2023001325A1/es unknown
- 2023-06-05 CO CONC2023/0007404A patent/CO2023007404A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20231952A1 (es) | 2023-12-06 |
| WO2022096736A1 (en) | 2022-05-12 |
| US20230406883A1 (en) | 2023-12-21 |
| CA3197916A1 (en) | 2022-05-12 |
| MX2023005408A (es) | 2023-07-25 |
| AU2021374843A1 (en) | 2023-06-08 |
| KR20230106616A (ko) | 2023-07-13 |
| AU2021374843A9 (en) | 2024-08-08 |
| JP2023551122A (ja) | 2023-12-07 |
| CO2023007404A2 (es) | 2023-07-10 |
| EP4240749A1 (en) | 2023-09-13 |
| IL302745A (en) | 2023-07-01 |
| CN116745310A (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023007404A2 (es) | Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina | |
| NI201100084A (es) | Antagonistas del receptor de orexina de isonicotinamida. | |
| MX2021006804A (es) | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. | |
| ECSP21051067A (es) | Amidas de pirrolidina III sustituidas | |
| CO6351717A2 (es) | Tripiridil carboxamida como antagonista del receptor de orexina | |
| NI201300043A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| ECSP067121A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| CR10060A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| ECSP11011163A (es) | Pirimidin-4-carboxamidas cíclicas en calidad de antagonistas del receptor CCR2 para el tratamiento de inflamación, asma y EPOC | |
| CR10682A (es) | Compuestos de tiazol pirazolopirimidina | |
| UY31619A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
| CL2016002348A1 (es) | Agonistas del receptor muscarínico | |
| UY34530A (es) | Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1) | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| CO6351735A2 (es) | Compuestos de azaindazol como antagonistas del receptor de ccr1 | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
| CR8775A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| CR11562A (es) | Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina | |
| MX2020006355A (es) | Pirrolidinamidas ii sustituidas. | |
| MX2019004782A (es) | Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño. | |
| MX2015008733A (es) | Derivados de 1,2,3-triazol-4-amina para el tratamiento de enfermedades y transtornos relacionados con receptores sigma. |